Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements

Provided By GlobeNewswire

Last update: Sep 3, 2024

Highlights

Humacao, PR and New York, NY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP), a Nasdaq Global Market^®listed special purpose acquisition company, ("PowerUp"), have entered into a definitive agreement and plan of merger (the "Merger Agreement"). The proposed business combination (the "Business Combination") is subject to customary closing conditions, including regulatory and stockholder approvals. The combined public company is expected to be named "Aspire Biopharma Holdings, Inc." and plans to list its common stock on Nasdaq under the new ticker symbol "ASPH", subject to the approval of its listing application.